Steroid Mouth Rinse Prevents Stomatitis with Everolimus

TON May 2016 Vol 9 No 3 - Breast Cancer
Wayne Kuznar

San Antonio, TX—A steroid mouthwash can reduce the incidence of stomatitis associated with the use of everoli­mus. Data from the first prospective trial of prophylactic use of a steroid mouth rinse demonstrated a 26% incidence of stomatitis among patients with metastatic breast cancer who used the mouth rinse versus 67% in historical controls, said Vicky E. Jones, MD, at the 2015 San Antonio Breast Cancer Symposium.

The ongoing phase 2 study evaluated 2 different steroid-based mouth rinses for the prevention or amelioration of oral stomatitis in postmenopausal patients within the US Oncology Network with hormone receptor (HR)-positive metastatic breast cancer treated with everolimus.

“As we are expanding the use of everolimus into [the] metastatic breast cancer arena, stomatitis became a toxicity that needed to be addressed,” said Dr Jones, US Oncology Research, Inc, The Woodlands, TX. “There were smaller studies that reported that steroid-containing mouth solutions seemed to make a difference, so the study was set up to look at 2 different mouth rinses. They were both compounded for purposes of the study so that they would be the same across all the study sites.”

Patients were randomized to 12 weeks of treatment with 1 of 2 oral rinses. In arm 1, patients were instructed to rinse with a 480-mL recipe containing 320 mL of oral Benadryl, 2 g of tetracycline, 80 mg of hydrocortisone, and 40 mL of nystatin suspension. Arm 2 was assigned to an oral solution of prednisolone 15 mg/5 mL.

Patients were instructed to swish and expectorate 10 mL of the assigned mouthwash 4 times each day. If symptoms of pharyngitis developed, they could also gargle with the assigned rinse 4 times per day.

The primary objective was to determine the incidence of grade ≥2 stomatitis during the first 12 weeks of treatment. A total of 48 patients were randomized, and 47 received the study treatment.

“Stomatitis tends to be an early phenomenon with everolimus, so the 12 weeks covered that time period pretty well,” said Dr Jones.

The incidence of all-grade stomatitis and related events was 26%. The incidence of grade ≥2 stomatitis was 9%. Of the 4 patients with grade ≥2 stomatitis, 1 developed it within the first 2 weeks and 3 within the first 30 days. No patient experienced grade 3 stomatitis.

For 3 of the 4 patients who developed grade ≥2 stomatitis, no action was taken, and an everolimus dose was delayed in the fourth patient. No patients required everolimus dose reduction.

One patient developed oral candidiasis while on the mouth rinse. No patients stopped the prophylactic rinse due to treatment-related toxicity.

By comparison, in the BOLERO-2 trial in patients with HR-positive metastatic breast cancer who were treated with exemestane plus everolimus, the incidence of all-grade stomatitis or related adverse events was 67%, with 24% developing grade 2 and 8% developing grade 3 stomatitis. In BOLERO-2, one-fourth of patients required everolimus dose reduction for stomatitis, noted Dr Jones.

“The bottom line is that the mouth rinses were well tolerated with very few side effects,” she said. “Only one patient developed thrush, and nobody stopped because of toxicity of the mouth rinse.”

The incidence of stomatitis on each study arm will be available when all patients in the trial have been accrued.

Reference

Jones VE, Jensen LL, McIntyre KJ, et al. Evaluation of miracle mouthwash (MMW) plus hydrocortisone versus prednisolone mouth rinses as prophylaxis for everoli­mus-associated stomatitis: preliminary results of a randomized phase II study. Poster presented at: 2015 San Antonio Breast Cancer Symposium; December 5-8, 2015; San Antonio, TX. Abstract P1-15-06. http://sabcs15.posterview.com/nosl/i/P1-15-06. Accessed January 4, 2016.

Related Items
Talzenna (Talazoparib) New PARP Inhibitor Approved for the Treatment of HER2-Negative Advanced Breast Cancer with Germline BRCA Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in Breast Cancer, FDA Approvals
FDA Expands Indication for Kadcyla to Include the Adjuvant Treatment of HER2-Positive Early Breast Cancer
Yvette Florio Lane
Web Exclusives published on May 14, 2019 in Breast Cancer, FDA Approvals, In the News
T-DM1 Reduces Residual Invasive Disease in Patients with HER2-Positive Breast Cancer After Chemotherapy
Phoebe Starr
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Breast Cancer
Updated NCCN Treatment Guideline for CML Establishes Criteria for Stopping TKI Therapy
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in NCCN Updates
Atezolizumab plus Nab-Paclitaxel for Triple-Negative Breast Cancer with PD-L1 Expression
Phoebe Starr
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Breast Cancer
Immunotherapy Strategies in the Updated NCCN Guideline for NSCLC Hinge on PD-L1 Testing
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in NCCN Updates
Updated NCCN Breast Cancer Guideline Expands Treatment Recommendations for HR-Positive, HER2-Negative Disease
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Breast Cancer, NCCN Updates
Immunotherapy Combination Extends Survival in Advanced Refractory Colorectal Cancer
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Colorectal Cancer
Tumor Metabolism-Altering Regimen Achieves Clinical Benefit in Metastatic Pancreatic Cancer
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Pancreatic Cancer
CAR T-Cell Therapy Fills Unmet Needs in Leukemia and Lymphoma
Wayne Kuznar
TOP - May 2019, Vol 12, No 2 published on May 13, 2019 in Immunotherapy
Last modified: May 18, 2016